On July 17, Corona Remedies, which is preparing for its IPO, announced the acquisition of seven pharmaceutical brands from Bayer AG’s Indian division. This marks the company’s fourth strategic acquisition from a multinational firm. Financial terms of the deal were not disclosed.
Effective from July 16, the acquisition includes the cardiology brand Noklot and six women’s healthcare brands: Fostine, Luprofact, Menodac, Ovidac, Spye, and Vageston.
The acquisition enhances Corona Remedies’ portfolio in cardiology and women’s health, while also marking its entry into the anti-platelet drug segment—a market in India currently valued at ₹1,507 crore, growing at an annual rate of 8%.
With cardiovascular diseases on the rise and now among the leading causes of death in India, the demand for antiplatelet medications—critical in preventing heart attacks and strokes—is steadily increasing. This move strategically positions Corona Remedies to cater to the expanding need for cardiac care and reproductive health solutions in the Indian market.